araag2/HINT huggingface dataset:
Clinical trial NCT00622635 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 300 μg, placebo to indacaterol, salmeterol 50 μg
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as
             classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
             Guidelines, 2006) and:

               1. Smoking history of at least 20 pack-years

               2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30%
                  of the predicted normal value

               3. Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

        Exclusion Criteria:

          -  Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to
             screening or during the run-in period

          -  Patients requiring long-term oxygen therapy (> 15 hours a day) for chronic hypoxemia

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Any patient with active cancer or a history of cancer with less than 5 years
             disease-free survival time

          -  Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured
             at screening or randomization is prolonged

          -  Patients who have been vaccinated with live attenuated vaccines within 30 days prior
             to screening or during the run-in period

          -  Patients unable to successfully use a dry powder inhaler device or perform spirometry
             measurements

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00679731 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: abt-874, methotrexate
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Psoriasis for 6 MO.. BSA 10%, PASI 12 or above, PGA 3 or above

        Exclusion Criteria:

          -  Previous exposure to anti-IL 12
Clinical trial NCT00289900 (phase 3, status: completed)
Conditions: mixed hyperlipidemia
ICD codes: E78.2
Drugs: mk-0524a, atorvastatin, simvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Participant 18 to 80 years of age with Mixed Hyperlipidemia with LDL-C between 130 and
             190 mg/dL and Triglycerides between 150 and 500 mg/dL

        Exclusion Criteria:

          -  Pregnant or lactating women, or women intending to become pregnant

          -  Diabetes mellitus that is poorly controlled, newly diagnosed, or taking new or
             recently adjusted antidiabetic therapy (with the exception of ± 10 units of insulin)

          -  Human immunodeficiency virus (HIV) positive

          -  Any of the following within the past 3 months: heart attack, stoke, heart bypass
             surgery, unstable angina, angioplasty

          -  Active or chronic liver disease
Clinical trial NCT00481819 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: fk506mr, prograf, mycophenolate mofetil, methylprednisolone, prednisolone
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent with the date of the patient must be obtained.

          -  Patient between 18-70 years of age receiving the primary kidney.

          -  Female patients must have a negative pregnancy test prior to the enrolment.

          -  Female patients of child bearing potential must agree to practice effective birth
             control during the study.

        Exclusion Criteria:

          -  Kidney re-transplantation patients or received an organ transplantation other than a
             kidney.

          -  PRA>10% in the previous 6 months.

          -  Patient who need antibody induction therapy.

          -  Patient with significant liver disease, defined as having continuously elevated >2
             times of SGPT and/or SGOT and/or total bilirubin levels during the past 28 days.

          -  Patient with severe infection requiring treatment, and/or severe diarrhea, vomiting,
             active upper gastrointestinal tract malabsorption or active peptic ulcer.

          -  Patient has any history of severe cardiovascular, respiratory disease; or history of
             malignancy.

          -  Patient is HIV or HBsAg positive.

          -  Patient is allergic to Prograf or macrolide antibiotics.
Clinical trial NCT00421122 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: budesonide/formoterol (symbicort), budesonide (pulmicort), terbutaline sulfate (bricasol)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed and dated inform consent

          -  Out-patient, clinical diagnosis of COPD

          -  Men or women at the age of 40 or over

        Exclusion Criteria:

          -  A history of asthma

          -  Seasonal allergic rhinitis before 40 years of age

          -  Patients with significant or unstable ischemic heart disease, arrhythmia,
             cardiomyopathy, heart failure, uncontrolled hypertension as defined by the
             investigator or other disorder
Clinical trial NCT01499082 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: hoe901-u300 (new formulation of insulin glargine), lantus (insulin glargine)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion criteria :

          -  Participants with type 2 diabetes mellitus

          -  Substudy inclusion criteria:

               -  Completion of the 6-month study period in main study (Visit 10)

               -  Randomized and treated with insulin glargine new formulation during the 6-month
                  treatment period (Baseline - month 6)

        Exclusion criteria:

          -  Age less than (<) 18 years

          -  HbA1c <7.0% or greater than (>) 10% at screening

          -  Diabetes other than type 2 diabetes mellitus

          -  Less than 1 year on basal plus mealtime insulin and self-monitoring of blood glucose

          -  Any contraindication to use of insulin glargine as defined in the national product
             label

          -  Participants using human regular insulin as mealtime insulin in the last 3 months
             before screening visit

          -  Use of an insulin pump in the last 6 months before screening visit

          -  Initiation of new glucose-lowering agents and/or weight loss drugs in the last 3
             months before screening visit

          -  History or presence of significant diabetic retinopathy or macular edema likely to
             require laser or injectable drugs or surgical treatment during the study period

          -  Pregnant or breast-feeding women or women who intend to become pregnant during the
             study period

          -  Substudy exclusion criteria:

               -  Participant not willing to use the adaptable injection intervals on at least two
                  days per week

        The above information is not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00345059 (phase 3, status: terminated)
Conditions: advanced non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, vinorelbine, gemcitabine, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Age > 18

          -  Histological diagnosis of non small-cell lung cancer (NSCLC)

          -  Stage IIIb or Stage IV disease (in IIIb, previous treatment with chemotherapy +
             radiotherapy, or metastatic supraclavicular lymph nodes or pleural effusion)

          -  Disease in progression

          -  Previous chemotherapy with platinum-derivative (and with > 21 days from last
             administration)

        Exclusion Criteria:

          -  ECOG performance status > 2

          -  Age > 75 years

          -  History of malignant neoplasm within the previous 5 years (except for baso- or
             spino-cellular skin carcinoma and in-situ carcinoma of the uterine cervix, provided
             they are being adequately treated)

          -  Previous treatment with docetaxel

          -  Presence of symptomatic cerebral metastasis

          -  Neutrophils < 2.0 x 109/l, platelets < 100,000/l, hemoglobin > 10g/dl

          -  Bilirubin < 1.5 x the upper normal limit

          -  SGOT , SGPT, or bilirubin > 1.25 x the upper normal limits except in the presence of
             hepatic metastasis

          -  Creatinine >1.25 x the upper normal limit

          -  Any concomitant pathology that would, in the Investigator's opinion, contraindicate
             the use of the drugs in the protocol

          -  Inability to comply with follow up

          -  Pregnant or nursing females
Clinical trial NCT01289119 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: alogliptin, placebo to alogliptin, metformin, pioglitazone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has a historical diagnosis of Type 2 Diabetes Mellitus.

          -  Has a body mass index between acceptable range.

          -  Is experiencing inadequate glycemic control.

          -  Body weight keeps constant.

          -  Females of childbearing potential and males who are sexually active agree to use
             routinely adequate contraception from signing of informed consent throughout the
             duration of the study and for 30 days after last dose.

        Exclusion Criteria:

          -  Has participated in another clinical study within the past 90 days or has received any
             investigational compound within 30 days prior to randomization.

          -  Has a systolic blood pressure beyond the acceptable range at Screening visit.

          -  Has New York Heart Association Class III or IV heart failure regardless of therapy.

          -  Has any major illness or debility that in the investigator's opinion prohibits the
             subject from completing the study.

          -  Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.
Clinical trial NCT00368277 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: aliskiren, ramipril, hydrochlorothiazide, amlodipine
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients ≥ 65 years old.

          -  Patients with essential hypertension with an msSBP ≥ 140 mmHg and < 180 mmHg, and
             msDBP < 110 mmHg at Visits 2 and 3. (Visit 201 was deleted by the Administrative
             Changes document.)

          -  Patients must have had a difference in msSBP of ≤ 20 mmHg between Visit 3 and the
             visit immediately prior to Visit 3.

          -  Patients who were eligible and able to participate in the study, and who consented to
             do so after the purpose and nature of the investigation had been explained to them
             (written informed consent).

        Exclusion Criteria:

          -  History of renal artery stenosis.

          -  Known Keith-Wagener grade III or IV hypertensive retinopathy.

          -  History of hypertensive encephalopathy.

          -  Current diagnosis of heart failure (New York Heart Association Class III-IV).

          -  History of transient ischemic cerebral attack or cerebrovascular accident within 6
             months.

          -  History of myocardial infarction, bypass surgery, or any percutaneous coronary
             intervention within 6 months.

          -  Current unstable angina pectoris. Patients on a stable dose of oral or topical
             nitrates or beta blockers for angina were acceptable.

          -  Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.

          -  Clinically significant valvular heart disease.

          -  Concurrent use of any antihypersensitive medications except a stable dose 3 months
             prior to visit 1 of alpha adrenergic blockers for benign prostatic hypertrophy (e.g.,
             Flomax for BPH), beta blockers for angina, or beta blockers ophthalmic preparations.
Clinical trial NCT00464243 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: volinanserin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
             Disorders (Fourth Edition) criteria

          -  Disturbances of sleep maintenance criteria based on patient's information related to
             sleep pattern during the preceding month

          -  Specific criteria based on the NPSG recordings during the screening nights

        Exclusion Criteria:

          -  Females who are lactating or who are pregnant

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month

          -  Consumption of xanthine-containing beverages (i.e. tea, coffee, cola) comprising more
             than 5 cups/day

          -  Participation in another trial having received study medication within 1 month before
             the screening visit

          -  Body Mass Index ≥ 33

          -  Use of over-the-counter medications such as tryptophan, valerian root, kava,
             melatonin, St. John's Wort, Alluna or prescription sleep medication

          -  Use of any substance with psychotropic effects or properties know to affect sleep/wake

          -  History of primary hypersomnia, narcolepsy, breathing-related sleep disorder,
             circadian rhythm sleep disorder, parasomnia, dyssomnia

          -  Clinically significant, severe or unstable, acute or chronically progressive medical
             or surgical disorder

          -  Positive qualitative urine drug screen (opiates, cocaine, amphetamine…)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00412217 (phase 3, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: placebo, erlotinib
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    the study was terminated because recruitment was too slow.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults greater than or equal to (≥) 18 years of age

          -  Curatively treated head and neck squamous cell cancer with T3-T4 and/or N2-N3
             pathology, with or without other findings of poor prognosis such as extranodal
             extension, positive resection margins, and perineural or vascular involvement

          -  Eastern Cooperative Oncology Group (ECOG) status of 0 to 2

        Exclusion Criteria:

          -  Macroscopic residual disease after surgery

          -  Previous treatment with anti-epidermal growth factor receptor (anti-EGFR) targeted
             therapies
Clinical trial NCT00631371 (phase 3, status: completed)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: bevacizumab, temsirolimus, bevacizumab, interferon-alfa 9mu
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CN1N=NC2=C(N=CN2C1=O)C(N)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically and/or cytologically confirmed to have advanced renal cell carcinoma
             (RCC)

          -  Majority component of conventional clear-cell type is mandatory

          -  At least 1 measurable lesion (per RECIST)

        Exclusion Criteria:

          -  Prior systemic treatment for RCC

          -  Evidence of current or prior central nervous system (CNS) metastases

          -  Cardiovascular disease

          -  Pregnant or nursing women

          -  Additional criteria applies
Clinical trial NCT00494871 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: rivaroxaban (xarelto, bay59-7939), warfarin, rivaroxaban placebo, warfarin placebo
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, S1SSSSSSS1, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, S1SSSSSSS1
Eligibility criteria:

        Inclusion Criteria:

          -  20 years or older

          -  Japanese male or female

          -  Non- valvular atrial fibrillation documented by ECG

          -  Patients with a risk of stroke and non-CNS systemic embolism

        Exclusion Criteria:

          -  Significant mitral stenosis

          -  Patients in whom anticoagulants are contraindicated
Clinical trial NCT00638131 (phase 3, status: terminated)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Reason stopped: 
    problem of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women ≥ 18 years of age with a body weight of ≥ 40 kg;

          -  For female patients, only non-pregnant women who are surgically sterile,
             postmenopausal or have documented infertility (over 50 years of age and amenorrheic
             for at least 1 year), or those of childbearing potential using intrauterine devices
             (IUDs);

          -  Patients diagnosed Type 2 diabetes with overt nephropathy (urinary albumin excretion ≥
             300mg/24h);

          -  Patients on current treatment with angiotensin II receptor blockers for ≥ 3 months;

          -  Patients stable for at least 3 months prior to screening (no change in medications for
             diabetic nephropathy);

          -  Provide written informed consent;

        Exclusion Criteria:

          -  Patients with a history of pulmonary chronic obstructive disease, cardiac failure or
             coronary artery disease;

          -  Patients with documented cancers, acute infections or chronic inflammatory diseases;

          -  Patients who are pregnant or breast-feeding;

          -  Patients with known hepatic disorders or AST and ∕or ALT upper than normal limit;

          -  Patients with hemoglobin or hematocrit that is ≥ 30% below the normal range (patients
             with secondary polycythemia are permitted);

          -  Patients with systolic blood pressure < 110mm Hg;

          -  Patients with plasmatic albumin level < 30g/L;

          -  Patients with a documented creatinine clearance ≤ 60ml/min;

          -  Patients on anticoagulants or anti-inflammatory drugs, including cyclooxygenase
             inhibitors, AINS, prednisone and immunosuppressive drugs, platelet aggregation
             inhibitors, except low dose aspirin, ACE inhibitors, antidiabetic agents
             (rosiglitazone, pioglitazone) and antioxidants (vitamin E)(except statins or low-dose
             aspirin ≤ 80mg/day);

          -  Patients on treatment or planned treatment with another investigational drug;

          -  Patients who are receiving an endothelin receptor antagonist, phosphodiesterase type 5
             inhibitor, or with a prostanoid (excluding acute administration during a
             catheterization procedure to test vascular reactivity) within 2 months of inclusion;

          -  Patients who are receiving calcineurin-inhibitors (i.e., cyclosporine A and
             tacrolimus), fluconazole, glibenclamide (glyburide) at inclusion or are expected to
             receive any of these drugs during the study;

          -  Patients with a known hypersensitivity to bosentan or any of the excipients;